Page 128 - ebook HCC

GENEV
EASL
PROGRAMME AND ABSTRACTSAND ABSTRACTS
126
127
126 PROGRAMME GENEVA, SWITZERLANDA, SWITZERLAND EASL HCC SUMMITHCC SUMMIT 127
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number B22 Poster Board Number B23
LONG-TERM IMPROVEMENT OF MORTALITY GLYCOMIC ANALYSIS OF SAFFRON-BASED
WITH REDUCED HEPATOCELLULAR PROTECTION AGAINST HEPATOCELLULAR
CARCINOMA (HCC) INCIDENCE IN PATIENTS CARCINOMA
WITH CHRONIC HEPATITIS B VIRUS (HBV)
INFECTION TREATED WITH NUCLEOTIDE 1 Biology, UAE University, Al-Ain, United Arab Emirates, Ezose, NJ, United States,
Amr Amin , Diane McCarthy , Nazar Zaki
3
1
2
2
ANALOGUES 3 College of IT, Al-Ain, United Arab Emirates
Corresponding author’s e-mail: a.amin@uaeu.ac.ae
Yuki Matsumura , Yuki Nakada , Mina Hamano , Miho Chiba ,
1
1
1
1
Masafumi Naito , Toshifumi Ito 1
1
1 Osaka Koseinenkin Hospital, Osaka, Japan Introduction: Hepatocellular carcinoma (HCC) is one of the most common types of cancer
worldwide. Hepatocellular alterations that normally precede the appearance of HCC would
Corresponding author’s e-mail: matsumura@okn.gr.jp ultimately cause a discrepancy in the microenvironment of liver cells and may result in
changes in the proteomic profile of liver cells.
Introduction: Chronic HBV infection could lead to both liver cirrhosis (LC) and HCC. Aims: The aim of the present study was to evaluate, in a rat model of liver cancer,
NAs like lamivudine, adefovir, and entecavir were recently administered for chronic HBV qualitative and quantitative changes in N-linked glycosylation of proteins that occur in
infected patients. response to HCC and/or treatment with saffron-based biomolecules (SBB).
BASIC POSTER ABSTRACTS incidence reduction referring to characteristics of clinical backgrounds and laboratory Methodology: Liver tissue samples of 4 groups of rats- 1) seven normal (non-tumor- BASIC POSTER ABSTRACTS
Aims: Aim of this study was to clarify contribution to mortality improvement and HCC
bearing) rats; 2) four untreated tumor-bearing rats; 3) seven tumor-bearing rats treated
findings with applying NAs for chronic HBV infection.
with CH and 3) nine tumor-bearing rats treated with SH- were extracted and the liver
lysates were used for biochemical and GlycanMap® analyses. Briefly, GlycanMap®
Methodology: We excluded patients developing HCC within 6 months after the NAs-
analysis is high-throughput assay that provides a structural and quantitative readout of
treatment. One hundred chronic HBV infected patients taking NAs after January 2001
were enrolled for this retrospective study. We analyzed clinical backgrounds, mortality,
to matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
HCC occurrence, and changes in laboratory data. protein-associated glycans using a unique, automated 96-well assay technology coupled
TOF MS) and custom bioinformatics.
Results: The enrolled patients consisted of 63 chronic hepatitis (CH) patients and 37 Results: SBB decreased the area of placental glutathione-S-transferase-positive foci
LC patients. In 50 months median observed period, 19 patients developed HCC by in livers of DEN-treated rats. Furthermore, saffron counteracted DEN-induced oxidative
September 2013, dividing those patients into two groups, non-HCC and HCC. Their stress in rats as assessed by restoration of superoxide dismutase and catalase levels and
baseline characteristics were not different. The laboratory data were improved one year diminishing of myeloperoxidase activity, malondialdehyde and protein carbonyl formation
after NAs administration comparing to baseline screening with statistical significance. The in liver. 36 N-linked glycans were detected and quantified. 9 glycans showed statistically
cumulative HCC incidence rates at 5 years were 13% and 43% for the CH patients and significant differences between the groups. Of which, five high mannose glycans (G Man ,
the LC patients, respectively (P < 0.001). No HCC have developed over 4 years after NAs Man , Man , Man ,and Man ) were elevated in tumor-bearing animals as compared to
9
1
treatment. The cumulative survival probabilities at 5 yeas were 100% and 74.9% for the normals while four Glycans (G0 and bisG0 and their corresponding fucosylated glycans
8
7
9
6
CH patients and the LC patients, respectively (P < 0.02). G0F and bisG0F) were elevated in the SH treatment group compared to the CH treatment
and normal groups.
Conclusions: NAs-treatments for chronic HBV infected patients could suppress HCC
development with HBV-DNA reduction, leading to improvement of long-term mortality in
both CH and LC.